Latest Cladribine Stories
This report provides perspective on the MS landscape in light of Merck Seronoâ€™s decision to discontinue development and marketing of cladribine for MS. Scottsdale, AZ (PRWEB) June 27, 2011 MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled â€œThought Leader Insight & Analysis: Multiple Sclerosis,â€ designed to provide critical strategic insight for pharma and biotech companies...
ROCKLAND, Mass., March 2, 2011 - EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that it received a complete response letter (CRL) from the U.S.
BURLINGTON, Mass., Dec.
ROCKLAND, Mass., Nov. 26, 2010 /PRNewswire/ -- EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today that the U.S.
WALTHAM, Mass., Aug.
ROCKLAND, Mass., July 28 /PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that the U.S.
WALTHAM, Mass., July 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch of several high-priced novel disease-modifying therapies--including the first oral agents approved for the indication--will fuel modest 3 percent annual growth in the multiple sclerosis (MS) drug market through 2019, coupled with increasing use of current and emerging monoclonal antibodies. The Pharmacor 2010...
ROCKLAND, Mass., Jan.
A new drug for multiple sclerosis promises to change the lives of the 100,000 people in the UK who have the condition, say researchers at Queen Mary, University of London.
CAMBRIDGE, Mass., Jan.
- A trick or prank.